SuzanneGeorgeMD

Oncology • Boston, MA

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. George is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. George's full profile

Already have an account?

Office
44 Binney St
# Dana
Boston, MA 02115
Phone+1 617-632-5204

Fax+1 617-632-3408

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
Tufts Medical CenterResidency, Internal Medicine, 1997 - 1998
University of North Carolina HospitalsResidency, Internal Medicine, 1995 - 1997
University of Massachusetts Medical SchoolClass of 1995

Certifications & Licensure

NH State Medical License 2004 - Present
MA State Medical License 1999 - 2026
NC State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2012-2013

Clinical Trials

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas Start of enrollment: 2003 Feb 01
Completed
Phase 2
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Start of enrollment: 2009 Feb 01
Completed
Phase 2
RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms Start of enrollment: 2009 Jul 01
Completed
Phase 1
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients Start of enrollment: 2010 Jan 01
Terminated
Phase 3
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Start of enrollment: 2010 Feb 01
Completed
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST Start of enrollment: 2014 Jul 01
Completed
Phase 1
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas Start of enrollment: 2015 Aug 01
Completed
Phase 2
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Start of enrollment: 2019 Mar 13
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

363 citations
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Suzanne George, Diana Miao, George D. Demetri, Dennis Adeegbe, Scott J. Rodig
Immunity. 2017-02-21
152 citations
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study
Eytan Ben-Ami, Constance M. Barysauskas, Sarah Solomon, Kadija Tahlil, Rita Malley
Cancer. 2017-09-01
56 citations
Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Margaret von Mehren, R Lor Randall, Robert S Benjamin, Sarah Boles, Marilyn M Bui
Journal of the National Comprehensive Cancer Network. 2016-06-01

Journal Articles

Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical Advances
M C Heinrich, S George, M L Hemming, Annals of Oncology

Lectures

Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

Surgical treatment and other localized therapy for metastatic soft tissue sarcoma
George S, Raut CP, Demetri GD
http://www.uptodate.com/contents/surgical-treatment-and-other-localized-therapy-for-metastatic-soft-
UpToDate, Wolters Kluwer Health - 2012-07-03
Systemic treatment of metastatic soft tissue sarcoma
George S, Demetri GD
http://www.uptodate.com/contents/systemic-treatment-of-metastatic-soft-tissue-sarcoma
UpToDate, Wolters Kluwer Health - 2013-03-18

Press Mentions

Chemo-ICI Combo Promising in Soft Tissue SarcomaNovember 14th, 2021
The Life Raft Group, a Non-Profit Supporting Patients with GIST Cancer, Announces Members of the 2021 Medical Advisory BoardMarch 16th, 2021
Blueprint Medicines Wins FDA Approval for Its First DrugJanuary 9th, 2020
Join now to see all